Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABP 102 - Abpro Therapeutics/Celltrion

Next Previous
Drug Profile

ABP 102 - Abpro Therapeutics/Celltrion

Alternative Names: ABP-102 - Abpro Therapeutics; ABP-102 - Abpro Therapeutics/Celltrion; CT-P72

Latest Information Update: 06 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abpro Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Gastric cancer; Pancreatic cancer

Most Recent Events

  • 27 Apr 2025 Pharmacodynamics and adverse events data from preclinical trials in Breast cancer, Gastric cancer released by Abpro Therapeutics
  • 27 Apr 2025 Abpro Therapeutics plans clinical trials for HER2+ Breast cancer, Gastric cancer, Pancreatic cancer, Colon cancer, and other Cancer (Parenteral), in the first half of 2026
  • 25 Apr 2025 Updated pharmacodynamics and adverse events data from preclinical trials in Breast cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top